The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence

Katy Turner, Sharon Hutchinson, Peter Vickerman, Vivian Hope, Noel Craine, Norah Elizabeth Palmateer, Margaret May, Avril Taylor, Daniela De Angelis, Sheila Cameron , John Parry, Margaret Lyons, David J. Goldberg, Elizabeth Allen, Matthew Hickman

Research output: Contribution to journalArticle

216 Citations (Scopus)

Abstract

Aims  To investigate whether opiate substitution therapy (OST) and needle and
syringe programmes (NSP) can reduce hepatitis C virus (HCV) transmission among injecting drug users (IDUs). Design  Meta-analysis and pooled analysis, with logistic regression allowing adjustment for gender, injecting duration, crack
injecting and homelessness. Setting  Six UK sites (Birmingham, Bristol, Glasgow,
Leeds, London and Wales), community recruitment. Participants  A total of 2986
IDUs surveyed during 2001-09. Measurement  Questionnaire responses were used to define intervention categories for OST (on OST or not) and high NSP coverage (≥100% versus <100% needles per injection). The primary outcome was new HCV infection, measured as antibody seroconversion at follow-up or HCV antibody-negative/RNA-positive result in cross-sectional surveys. Findings 
Preliminary meta-analysis showed little evidence of heterogeneity between the
studies on the effects of OST (I(2)  = 48%, P = 0.09) and NSP (I(2)  = 0%,
P = 0.75), allowing data pooling. The analysis of both interventions included 919 subjects with 40 new HCV infections. Both receiving OST and high NSP coverage were associated with a reduction in new HCV infection [adjusted odds ratios (AORs) = 0.41, 95% confidence interval (CI): 0.21-0.82 and 0.48, 95% CI: 0.25-0.93, respectively]. Full harm reduction (on OST plus high NSP coverage)
reduced the odds of new HCV infection by nearly 80% (AOR = 0.21, 95% CI:
0.08-0.52). Full harm reduction was associated with a reduction in self-reported
needle sharing by 48% (AOR 0.52, 95% CI: 0.32-0.83) and mean injecting frequency by 20.8 injections per month (95% CI: -27.3 to -14.4). Conclusions  There is good evidence that uptake of opiate substitution therapy and high coverage of needle and syringe programmes can substantially reduce the risk of hepatitis C virus transmission among injecting drug users. Research is now required on whether the scaling-up of intervention exposure can reduce and limit hepatitis C virus prevalence in this population.
LanguageEnglish
Pages1978-1988
Number of pages11
JournalAddiction
Volume106
Issue number11
Early online date24 Aug 2011
DOIs
Publication statusPublished - 1 Nov 2011

Fingerprint

Opiate Alkaloids
Syringes
Drug Users
Hepacivirus
Needles
Virus Diseases
Incidence
Confidence Intervals
Harm Reduction
Meta-Analysis
Odds Ratio
Therapeutics
Needle Sharing
Homeless Persons
Injections
Hepatitis C Antibodies
Wales
Cross-Sectional Studies
Logistic Models
RNA

Keywords

  • HCV
  • methadone
  • needle and syringe programmes
  • opiate substitution treatment
  • primary prevention

Cite this

Turner, Katy ; Hutchinson, Sharon ; Vickerman, Peter ; Hope, Vivian ; Craine, Noel ; Palmateer, Norah Elizabeth ; May, Margaret ; Taylor, Avril ; De Angelis, Daniela ; Cameron , Sheila ; Parry, John ; Lyons, Margaret ; Goldberg, David J. ; Allen, Elizabeth ; Hickman, Matthew. / The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users : pooling of UK evidence. In: Addiction. 2011 ; Vol. 106, No. 11. pp. 1978-1988.
@article{bc6429946d11461983a3584a8f0d0632,
title = "The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence",
abstract = "Aims  To investigate whether opiate substitution therapy (OST) and needle andsyringe programmes (NSP) can reduce hepatitis C virus (HCV) transmission among injecting drug users (IDUs). Design  Meta-analysis and pooled analysis, with logistic regression allowing adjustment for gender, injecting duration, crackinjecting and homelessness. Setting  Six UK sites (Birmingham, Bristol, Glasgow, Leeds, London and Wales), community recruitment. Participants  A total of 2986IDUs surveyed during 2001-09. Measurement  Questionnaire responses were used to define intervention categories for OST (on OST or not) and high NSP coverage (≥100{\%} versus <100{\%} needles per injection). The primary outcome was new HCV infection, measured as antibody seroconversion at follow-up or HCV antibody-negative/RNA-positive result in cross-sectional surveys. Findings Preliminary meta-analysis showed little evidence of heterogeneity between thestudies on the effects of OST (I(2)  = 48{\%}, P = 0.09) and NSP (I(2)  = 0{\%},P = 0.75), allowing data pooling. The analysis of both interventions included 919 subjects with 40 new HCV infections. Both receiving OST and high NSP coverage were associated with a reduction in new HCV infection [adjusted odds ratios (AORs) = 0.41, 95{\%} confidence interval (CI): 0.21-0.82 and 0.48, 95{\%} CI: 0.25-0.93, respectively]. Full harm reduction (on OST plus high NSP coverage)reduced the odds of new HCV infection by nearly 80{\%} (AOR = 0.21, 95{\%} CI:0.08-0.52). Full harm reduction was associated with a reduction in self-reported needle sharing by 48{\%} (AOR 0.52, 95{\%} CI: 0.32-0.83) and mean injecting frequency by 20.8 injections per month (95{\%} CI: -27.3 to -14.4). Conclusions  There is good evidence that uptake of opiate substitution therapy and high coverage of needle and syringe programmes can substantially reduce the risk of hepatitis C virus transmission among injecting drug users. Research is now required on whether the scaling-up of intervention exposure can reduce and limit hepatitis C virus prevalence in this population.",
keywords = "HCV, methadone, needle and syringe programmes, opiate substitution treatment, primary prevention",
author = "Katy Turner and Sharon Hutchinson and Peter Vickerman and Vivian Hope and Noel Craine and Palmateer, {Norah Elizabeth} and Margaret May and Avril Taylor and {De Angelis}, Daniela and Sheila Cameron and John Parry and Margaret Lyons and Goldberg, {David J.} and Elizabeth Allen and Matthew Hickman",
note = "Additional authors added",
year = "2011",
month = "11",
day = "1",
doi = "10.1111/j.1360-0443.2011.03515.x",
language = "English",
volume = "106",
pages = "1978--1988",
journal = "Addiction",
issn = "0965-2140",
number = "11",

}

Turner, K, Hutchinson, S, Vickerman, P, Hope, V, Craine, N, Palmateer, NE, May, M, Taylor, A, De Angelis, D, Cameron , S, Parry, J, Lyons, M, Goldberg, DJ, Allen, E & Hickman, M 2011, 'The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence' Addiction, vol. 106, no. 11, pp. 1978-1988. https://doi.org/10.1111/j.1360-0443.2011.03515.x

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users : pooling of UK evidence. / Turner, Katy; Hutchinson, Sharon; Vickerman, Peter; Hope, Vivian; Craine, Noel; Palmateer, Norah Elizabeth; May, Margaret; Taylor, Avril; De Angelis, Daniela; Cameron , Sheila; Parry, John; Lyons, Margaret; Goldberg, David J.; Allen, Elizabeth; Hickman, Matthew.

In: Addiction, Vol. 106, No. 11, 01.11.2011, p. 1978-1988.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users

T2 - Addiction

AU - Turner, Katy

AU - Hutchinson, Sharon

AU - Vickerman, Peter

AU - Hope, Vivian

AU - Craine, Noel

AU - Palmateer, Norah Elizabeth

AU - May, Margaret

AU - Taylor, Avril

AU - De Angelis, Daniela

AU - Cameron , Sheila

AU - Parry, John

AU - Lyons, Margaret

AU - Goldberg, David J.

AU - Allen, Elizabeth

AU - Hickman, Matthew

N1 - Additional authors added

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Aims  To investigate whether opiate substitution therapy (OST) and needle andsyringe programmes (NSP) can reduce hepatitis C virus (HCV) transmission among injecting drug users (IDUs). Design  Meta-analysis and pooled analysis, with logistic regression allowing adjustment for gender, injecting duration, crackinjecting and homelessness. Setting  Six UK sites (Birmingham, Bristol, Glasgow, Leeds, London and Wales), community recruitment. Participants  A total of 2986IDUs surveyed during 2001-09. Measurement  Questionnaire responses were used to define intervention categories for OST (on OST or not) and high NSP coverage (≥100% versus <100% needles per injection). The primary outcome was new HCV infection, measured as antibody seroconversion at follow-up or HCV antibody-negative/RNA-positive result in cross-sectional surveys. Findings Preliminary meta-analysis showed little evidence of heterogeneity between thestudies on the effects of OST (I(2)  = 48%, P = 0.09) and NSP (I(2)  = 0%,P = 0.75), allowing data pooling. The analysis of both interventions included 919 subjects with 40 new HCV infections. Both receiving OST and high NSP coverage were associated with a reduction in new HCV infection [adjusted odds ratios (AORs) = 0.41, 95% confidence interval (CI): 0.21-0.82 and 0.48, 95% CI: 0.25-0.93, respectively]. Full harm reduction (on OST plus high NSP coverage)reduced the odds of new HCV infection by nearly 80% (AOR = 0.21, 95% CI:0.08-0.52). Full harm reduction was associated with a reduction in self-reported needle sharing by 48% (AOR 0.52, 95% CI: 0.32-0.83) and mean injecting frequency by 20.8 injections per month (95% CI: -27.3 to -14.4). Conclusions  There is good evidence that uptake of opiate substitution therapy and high coverage of needle and syringe programmes can substantially reduce the risk of hepatitis C virus transmission among injecting drug users. Research is now required on whether the scaling-up of intervention exposure can reduce and limit hepatitis C virus prevalence in this population.

AB - Aims  To investigate whether opiate substitution therapy (OST) and needle andsyringe programmes (NSP) can reduce hepatitis C virus (HCV) transmission among injecting drug users (IDUs). Design  Meta-analysis and pooled analysis, with logistic regression allowing adjustment for gender, injecting duration, crackinjecting and homelessness. Setting  Six UK sites (Birmingham, Bristol, Glasgow, Leeds, London and Wales), community recruitment. Participants  A total of 2986IDUs surveyed during 2001-09. Measurement  Questionnaire responses were used to define intervention categories for OST (on OST or not) and high NSP coverage (≥100% versus <100% needles per injection). The primary outcome was new HCV infection, measured as antibody seroconversion at follow-up or HCV antibody-negative/RNA-positive result in cross-sectional surveys. Findings Preliminary meta-analysis showed little evidence of heterogeneity between thestudies on the effects of OST (I(2)  = 48%, P = 0.09) and NSP (I(2)  = 0%,P = 0.75), allowing data pooling. The analysis of both interventions included 919 subjects with 40 new HCV infections. Both receiving OST and high NSP coverage were associated with a reduction in new HCV infection [adjusted odds ratios (AORs) = 0.41, 95% confidence interval (CI): 0.21-0.82 and 0.48, 95% CI: 0.25-0.93, respectively]. Full harm reduction (on OST plus high NSP coverage)reduced the odds of new HCV infection by nearly 80% (AOR = 0.21, 95% CI:0.08-0.52). Full harm reduction was associated with a reduction in self-reported needle sharing by 48% (AOR 0.52, 95% CI: 0.32-0.83) and mean injecting frequency by 20.8 injections per month (95% CI: -27.3 to -14.4). Conclusions  There is good evidence that uptake of opiate substitution therapy and high coverage of needle and syringe programmes can substantially reduce the risk of hepatitis C virus transmission among injecting drug users. Research is now required on whether the scaling-up of intervention exposure can reduce and limit hepatitis C virus prevalence in this population.

KW - HCV

KW - methadone

KW - needle and syringe programmes

KW - opiate substitution treatment

KW - primary prevention

UR - http://www.scopus.com/inward/record.url?scp=80053581086&partnerID=8YFLogxK

U2 - 10.1111/j.1360-0443.2011.03515.x

DO - 10.1111/j.1360-0443.2011.03515.x

M3 - Article

VL - 106

SP - 1978

EP - 1988

JO - Addiction

JF - Addiction

SN - 0965-2140

IS - 11

ER -